https://www.selleckchem.com/products/apd334.html
Low symptom burden was reported by 27% of patients at baseline, 38% at 1-year, and 32% at 4 years post-AHCT. Predictors of low symptom burden at 1-year included low symptom burden at baseline OR 2.7 (1.8-4.1), p less then 0.0001; older age OR 2.1 (1.3-3.2), p = 0.0007; and was related to being employed OR 2.1 (1.4-3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT-BMT and subscale scores to population norms by 1-year post-transplant, though many patients continue to r
Мне нравится
Комментарий
Перепост
